Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VO659 multiple ascending dose intrathecal trial in SCA1, SCA3, and Huntington's disease
NL-OMON61005Phase 2Recruiting
- Sponsor
- Vico Therapeutics
- Start
- Dec 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VO659 in spinocerebellar ataxia type 1 (SCA1), machado-joseph disease (MJD), Huntington disease (HD), sponsored by Vico Therapeutics. Started Dec 2022; status: recruiting.
02
Drugs
VO659
03
Conditions
spinocerebellar ataxia type 1 (SCA1)machado-joseph disease (MJD)Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON61005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61005.